Efficacy and Safety of ior®EPOCIM forChemotherapy- or Radiotherapy-Induced Anemia in Pediatric Cancer Patients
Med rev
; 12(3)july 2010. tab
Artigo
em Inglês
| CUMED
| ID: cum-55613
Biblioteca responsável:
CU425.1
ABSTRACT
INTRODUCTION:
Recombinant human erythropoietin (RHuEPO) is an erythropoiesis stimulating agent (ESA) used to treat anemia in patients with total or relative erythropoietin deficit. In cancer patients, it is administered to optimize hemoglobin (Hb) levels, correct anemia and reduce the need for transfusions. Cuba produces a RHuEPO, registered in 1998 as ior®EPOCIM, that is widely used in the national public health system, mainly to treat patients with anemia due to chronic kidney disease (CKD).OBJECTIVE:
Evaluate the efficacy and safety of ior®EPOCIM in pediatric cancer patients with anemia following chemotherapy or radiotherapy. The working hypothesis posed an Hb increase ≥15 g/l in 70 porcent of patients receiving ior®EPOCIM for 8 weeks(AU)
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Cuba
Base de dados:
CUMED
Assunto principal:
Eritropoetina
/
Anemia
Limite:
Humanos
Idioma:
Inglês
Revista:
Med rev
Ano de publicação:
2010
Tipo de documento:
Artigo
Instituição/País de afiliação:
Centro Nacional de Coordinación de Ensayos Clínicos/Cuba
/
Centro de Inmunología Molecular/Cuba
/
Hospital Pediátrico Juan Manuel Márquez/Cuba
/
Hospital Pediátrico Provincial/Cuba
/
Hospital Pediátrico Universitario José Luis Miranda/Cuba
/
Instituto Nacional de Hematología e Inmunología/Cuba
/
Instituto Nacional de Oncología y Radiobiología/Cuba